Even as studies and personal experiences repeatedly reflect the effectiveness of MOUD, a stigma about this approach and the medication persists, complicating efforts to help more people treat their opioid use disorders. The post Stigma Against Addiction Medication Limits Our Ability to End the Opioid Epidemic appeared first on MedCity News.
Bristol Myers Squibb is turning to the prime-editing technology of Prime Medicines for the R&D of new cell therapies for cancer and immunology. The pharma giant is paying $110 million up front to begin the collaboration. The post Gene-Editing Biotech Prime Medicine Strikes Up Cell Therapy R&D Alliance With Bristol Myers Squibb appeared first on…
By MATTHEW HOLT (I copied this here from Linked in where it 65+ comments just so I can find it when the story continues) Too painful to write up fully but I am on my 4th transfer in one phone call to MarinHealth trying to get an echocardiogram (EDIT-not an EKG as I originally wrote)….
At Frederick Health in Maryland, a determination to move forward into the future
At the heart of this fight are the patients whose lives quite literally depend on Medicaid. But we are also fighting for the caregivers who show up every day, the children who rely on stability, the families who rally around their loved ones, and all those whose lives are shaped by access to care. The…
Health and Human Services Secretary Robert F. Kennedy Jr. attracted notice — and in some quarters, outrage — for remarks about autism, a topic he’s clashed with scientists about for years. Kennedy held an April 16 press conference pegged to a new Centers for Disease Control and Prevention report that found the prevalence of autism rising to 1 in 31 among 8-year-olds, the…
What were the most popular posts on Healthcare Economist this year? Here are the top 10 in descending order: Valuing the Societal Impact of Medicines and Other Health Technologies: A User Guide to Current Best PracticesThe world is relying on the United States to get value-based drug pricing rightWhy is the market design for innovative…
The $6.5 billion raised by biopharmaceutical companies in the first quarter of 2025 is down nearly 20% year over year, according to a report from GlobalData. The firm says investors continue to favor later-stage companies with clinical data. The post Investor Caution Leads to Dip in Biotech Financings, GlobalData Report Shows appeared first on MedCity…
In this viewpoint article in the Journal of the International AIDS Society, KFF’s Jennifer Kates and co-authors Brian Honermann and Gregorio Millett of amfAR explore the implications of shifts in the global economic and political environment for the future of PEPFAR, the U.S government’s global HIV program created under President George W. Bush and credited…
By DANIEL STONE Joe Biden’s metastatic cancer diagnosis brings together two controversial issues: PSA testing for prostate cancer and presidential politics. To understand what is at stake Americans need basic information about PSA testing, and a frank discussion of the reasoning behind the prostate cancer screening decisions in the former president’s case. The dribble of…